Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors
- 24 November 2005
- journal article
- research article
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 18 (1) , 104-110
Abstract
Potential pharmacokinetic interactions between dapoxetine, a serotonin transporter inhibitor developed for the treatment of premature ejaculation (PE), and the phosphodiesterase-5 inhibitors tadalafil and sildenafil, agents used in the treatment of erectile dysfunction (ED), were investigated in an open-label, randomized, crossover study (n=24 men) comparing dapoxetine 60 mg, dapoxetine 60 mg+tadalafil 20 mg, and dapoxetine 60 mg+sildenafil 100 mg. Plasma concentrations of dapoxetine, tadalafil, and sildenafil were determined by liquid chromatography–tandem mass spectrometry. Tadalafil did not affect the pharmacokinetics of dapoxetine, whereas sildenafil increased the dapoxetine AUCinf by 22%; these effects were deemed not clinically important. Dapoxetine did not appear to affect the pharmacokinetics of tadalafil or sildenafil. Most adverse events were mild in nature. Thus, dapoxetine has no clinically important pharmacokinetic interactions with tadalafil or sildenafil, and the combinations are well tolerated.Keywords
This publication has 20 references indexed in Scilit:
- Premature Ejaculation: An Observational Study of Men and Their PartnersThe Journal of Sexual Medicine, 2005
- 740: Efficacy and Tolerability of Dapoxetine in the Treatment of Premature EjaculationJournal of Urology, 2005
- AUA GUIDELINE ON THE PHARMACOLOGIC MANAGEMENT OF PREMATURE EJACULATIONJournal of Urology, 2004
- Premature or Rapid Ejaculation: Heterosexual Couples' Perceptions of Men's Ejaculatory BehaviorArchives of Sexual Behavior, 2003
- How Does Premature Ejaculation Impact a Man’s Life?Journal of Sex & Marital Therapy, 2003
- Management of premature ejaculation – a comparison of treatment outcome in patients with and without erectile dysfunctionInternational Journal of Andrology, 2002
- FDA Evaluations Using In Vitro Metabolism to Predict and Interpret In Vivo Metabolic Drug‐Drug Interactions: Impact on LabelingThe Journal of Clinical Pharmacology, 1999
- Sexual Dysfunction in the United StatesJAMA, 1999
- Effect of SSRI Antidepressants on EjaculationJournal of Clinical Psychopharmacology, 1998
- Premature Ejaculation: A psychophysiological reviewJournal of Sex & Marital Therapy, 1997